Source: Eur Respir J 2007; 30: 1014-1017
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Perri D., Cole D. E. C., Friedman O., Piliotis E., Mintz S., Adhikari N. K. J.. Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase. Eur Respir J 2007; 30: 1014-1017

Member's Comments

No comment yet.

Related content which might interest you: TNF-α polymorphism as a prognostic marker for MTX efficacy in progressive pulmonary sarcoidosis Source: International Congress 2016 – Sarcoidosis Year: 2016 Association of diffuse alveolar hemorrhage with VKORC1, CYP2C9, and CYP2C19 polymorphisms Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 The associations of polymorphism C3435T multidrug resistance gene (MDR1) and regimen of inhaled glucocorticosteroid therapy in bronchial asthma (BA) patients Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Therapeutic options for sarcoidosis: old and new Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005 Year: 2005 Idiopathic pulmonary haemosiderosis revisited Source: Eur Respir J 2004; 24: 162-169 Year: 2004 Association between N-acetyltransferase 2 polymorphism and antituberculosis drug-induced liver injury risk: a meta-analysis Source: International Congress 2017 – Human susceptibility to tuberculosis Year: 2017 Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study Source: Eur Respir J 2011; 37: 129-135 Year: 2011 Pulmonary toxicity with mefloquine Source: Eur Respir J 2001; 18: 890-892 Year: 2001 The new approaches to the oral corticosteroid dosage decrease in patients with severe steroid-resistant bronchial asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005 Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005 Cytochrome CYP2C9 and vitamin K epoxide reductase gene polymorphisms in patients with pulmonary embolism treated with warfarin Source: Annual Congress 2007 - The role of gene polymorphisms in pulmonary disease susceptibility Year: 2007 Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations Source: Eur Respir J 2007; 30: 1143-1149 Year: 2007 Beyond corticosteroids: future prospects in the management of inflammation in COPD Source: Eur Respir Rev 2011; 20: 175-182 Year: 2011 Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Pharmacogenetics Source: Annual Congress 2005 - MP15 - Pharmacogenetics Year: 2005 N-acetyltransferase 2 and CYP2E1 polymorphisms do not increase the risk of antituberculosis drug-induced hepatotoxicity in caucasian population Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis Source: Eur Respir J 2011; 38: 1145-1150 Year: 2011 E-cadherin gene polymorphisms in asthma patients using inhaled corticosteroids Source: Eur Respir J 2011; 38: 1044-1052 Year: 2011 Single-nucleotide polymorphisms within TOLLIP and the efficacy of inhaled N-acetylcysteine therapy in idiopathic pulmonary fibrosis. Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019 Severe therapy resistant asthma Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=312 Year: 2003